Quest offers Biocept's liquid biopsy test

By staff writers

December 2, 2021 -- Quest Diagnostics has announced that it now offers the Target Selector NGS Lung Panel, a liquid biopsy test developed by molecular diagnostics firm Biocept. U.S. physicians can now order the panel directly from Quest.

Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.

With a doctor's order, patients provide a blood sample for testing at any of Quest's locations. The sample will then be forwarded to Biocept's CLIA-certified, College of American Pathologists (CAP)-accredited laboratory in San Diego for testing, Quest noted.

Diagnostics by drone? It may be closer than you think
The future is closer than you think. Unmanned aerial vehicles -- or drones -- delivering diagnostic tests or essential medicines to people may sound like...
Quest Diagnostics debuts new lab facility in NJ
Quest Diagnostics has finished integrating its Northeast regional operations into a new 25,000-sq-ft, next-generation lab facility in Clifton, NJ.
Cancer diagnoses still lower a year into COVID-19 pandemic
Fully a year into the COVID-19 pandemic, the rate of cancer diagnosis in the U.S. remained sharply below the rate before the outbreak, according to a...
Top companies earn 80% of revenue in IVD market
Most of the revenue in the IVD market is generated by fewer than 20 companies, according to a recent report by IVD market research firm Kalorama Information,...
Biocept launches molecular assay for BRAF mutations
Bicept has launched a molecular assay kit for the detection of BRAF mutations, which are commonly targeted in the treatment of solid tumors.

Copyright © 2021

Last Updated ka 12/2/2021 9:07:31 AM